Literature DB >> 22562523

Repeated exposure to MDMA and amphetamine: sensitization, cross-sensitization, and response to dopamine D₁- and D₂-like agonists.

Sarah Bradbury1, David Gittings, Susan Schenk.   

Abstract

RATIONALE: Acute exposure to (±) 3, 4-methylenedioxymethamphetamine (MDMA) produces hyperlocomotion that is preferentially expressed in the periphery of closed chambers. Following repeated administration, however, a sensitized hyperlocomotor response is preferentially expressed in the center of an activity box, so that the response resembles the more generalized activity that is produced by D-amphetamine (AMPH).
OBJECTIVES: The present study was designed to determine whether common neuroadaptations underlie the acute and sensitized responses to MDMA and AMPH.
METHODS: Rats were pretreated with five daily injections of MDMA (10.0 mg/kg), AMPH (2.0 mg/kg), or saline. Following a 2-day drug-free period, dose-response curves for hyperactivity produced by MDMA (2.5-10.0 mg/kg), AMPH (0.5-2.0 mg/kg), SKF-81297 (1.0-2.0 mg/kg), or quinpirole (0.25-1.0 mg/kg) were obtained.
RESULTS: Effects of MDMA and AMPH were increased by pretreatment with both drugs. The sensitized response following MDMA exposure was preferentially expressed in the center compartment, but, following AMPH pretreatment, the sensitized response was observed in both compartments. Cross-sensitization was unidirectional; AMPH pretreatment failed to sensitize to the effects of MDMA, but MDMA pretreatment sensitized to the effects of AMPH. MDMA and AMPH pretreatment produced marginal increases in the effects of SKF-81297. The response to quinpirole was, however, greater following MDMA, but not AMPH, pretreatment.
CONCLUSIONS: These data suggest that repeated MDMA exposure produces sensitization via a unique neurochemical effect.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22562523     DOI: 10.1007/s00213-012-2726-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  76 in total

1.  SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.

Authors:  Ronan Depoortere; Denis Boulay; Ghislaine Perrault; Olivier Bergis; Michel Decobert; Dominique Françon; Mireille Jung; Jacques Simiand; Philippe Soubrié; Bernard Scatton
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

2.  Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("ecstasy").

Authors:  K C Morley; J E Gallate; G E Hunt; P E Mallet; I S McGregor
Journal:  Eur J Pharmacol       Date:  2001-12-14       Impact factor: 4.432

3.  Temporal and environmental effects on quinpirole-induced biphasic locomotion in rats.

Authors:  C Van Hartesveldt
Journal:  Pharmacol Biochem Behav       Date:  1997-12       Impact factor: 3.533

4.  A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA.

Authors:  L H Gold; C B Hubner; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Long-term administration of d-amphetamine: progressive augmentation of motor activity and stereotypy.

Authors:  D S Segal; A J Mandell
Journal:  Pharmacol Biochem Behav       Date:  1974 Mar-Apr       Impact factor: 3.533

6.  Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat.

Authors:  Kirsten C Morley; Jonathon C Arnold; Iain S McGregor
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-06       Impact factor: 5.067

7.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain.

Authors:  D L Commins; G Vosmer; R M Virus; W L Woolverton; C R Schuster; L S Seiden
Journal:  J Pharmacol Exp Ther       Date:  1987-04       Impact factor: 4.030

8.  Effects of DOM and DMT in a proposed animal model of hallucinogenic activity.

Authors:  L M Adams; M A Geyer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1985       Impact factor: 5.067

9.  Effects of dopamine D1- or D2-like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)-MDMA.

Authors:  Marcy J Bubar; Kami M Pack; Paul S Frankel; Kathryn A Cunningham
Journal:  Psychopharmacology (Berl)       Date:  2004-04-03       Impact factor: 4.530

10.  Acute and sensitized response to 3,4-methylenedioxymethamphetamine in rats: different behavioral profiles reflected in different patterns of Fos expression.

Authors:  Joyce Colussi-Mas; Susan Schenk
Journal:  Eur J Neurosci       Date:  2008-11       Impact factor: 3.386

View more
  4 in total

Review 1.  The preclinical pharmacology of mephedrone; not just MDMA by another name.

Authors:  A R Green; M V King; S E Shortall; K C F Fone
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

2.  Repeated MDMA administration increases MDMA-produced locomotor activity and facilitates the acquisition of MDMA self-administration: role of dopamine D2 receptor mechanisms.

Authors:  Ross van de Wetering; Susan Schenk
Journal:  Psychopharmacology (Berl)       Date:  2017-02-10       Impact factor: 4.530

3.  A genetic reduction in the serotonin transporter differentially influences MDMA and heroin induced behaviours.

Authors:  Bridget W Brox; Bart A Ellenbroek
Journal:  Psychopharmacology (Berl)       Date:  2018-03-21       Impact factor: 4.530

4.  Comparison of the effects of abstinence on MDMA and cocaine self-administration in rats.

Authors:  Quenten Highgate; Susan Schenk
Journal:  Psychopharmacology (Berl)       Date:  2018-09-12       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.